526 related articles for article (PubMed ID: 22475820)
1. Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486.
Xu J; Li R; Workeneh B; Dong Y; Wang X; Hu Z
Kidney Int; 2012 Aug; 82(4):401-11. PubMed ID: 22475820
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-23a and MicroRNA-27a Mimic Exercise by Ameliorating CKD-Induced Muscle Atrophy.
Wang B; Zhang C; Zhang A; Cai H; Price SR; Wang XH
J Am Soc Nephrol; 2017 Sep; 28(9):2631-2640. PubMed ID: 28400445
[TBL] [Abstract][Full Text] [Related]
3. Suppression of atrogin-1 and MuRF1 prevents dexamethasone-induced atrophy of cultured myotubes.
Castillero E; Alamdari N; Lecker SH; Hasselgren PO
Metabolism; 2013 Oct; 62(10):1495-502. PubMed ID: 23866982
[TBL] [Abstract][Full Text] [Related]
4. Excessive glucocorticoid-induced muscle MuRF1 overexpression is independent of Akt/FoXO1 pathway.
Wang XJ; Xiao JJ; Liu L; Jiao HC; Lin H
Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 29046370
[TBL] [Abstract][Full Text] [Related]
5. The nuclear phosphatase SCP4 regulates FoxO transcription factors during muscle wasting in chronic kidney disease.
Liu X; Yu R; Sun L; Garibotto G; Lin X; Wang Y; Thomas SS; Li R; Hu Z
Kidney Int; 2017 Aug; 92(2):336-348. PubMed ID: 28506762
[TBL] [Abstract][Full Text] [Related]
6. Sepsis increases the expression and activity of the transcription factor Forkhead Box O 1 (FOXO1) in skeletal muscle by a glucocorticoid-dependent mechanism.
Smith IJ; Alamdari N; O'Neal P; Gonnella P; Aversa Z; Hasselgren PO
Int J Biochem Cell Biol; 2010 May; 42(5):701-11. PubMed ID: 20079455
[TBL] [Abstract][Full Text] [Related]
7. Muscle sparing in muscle RING finger 1 null mice: response to synthetic glucocorticoids.
Baehr LM; Furlow JD; Bodine SC
J Physiol; 2011 Oct; 589(Pt 19):4759-76. PubMed ID: 21807613
[TBL] [Abstract][Full Text] [Related]
8. Forkhead box O3 plays a role in skeletal muscle atrophy through expression of E3 ubiquitin ligases MuRF-1 and atrogin-1 in Cushing's syndrome.
Kang SH; Lee HA; Kim M; Lee E; Sohn UD; Kim I
Am J Physiol Endocrinol Metab; 2017 Jun; 312(6):E495-E507. PubMed ID: 28246104
[TBL] [Abstract][Full Text] [Related]
9. PPARβ/δ regulates glucocorticoid- and sepsis-induced FOXO1 activation and muscle wasting.
Castillero E; Alamdari N; Aversa Z; Gurav A; Hasselgren PO
PLoS One; 2013; 8(3):e59726. PubMed ID: 23555761
[TBL] [Abstract][Full Text] [Related]
10. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors.
Stitt TN; Drujan D; Clarke BA; Panaro F; Timofeyva Y; Kline WO; Gonzalez M; Yancopoulos GD; Glass DJ
Mol Cell; 2004 May; 14(3):395-403. PubMed ID: 15125842
[TBL] [Abstract][Full Text] [Related]
11. Involvement of the FoxO1/MuRF1/Atrogin-1 Signaling Pathway in the Oxidative Stress-Induced Atrophy of Cultured Chronic Obstructive Pulmonary Disease Myotubes.
Pomiès P; Blaquière M; Maury J; Mercier J; Gouzi F; Hayot M
PLoS One; 2016; 11(8):e0160092. PubMed ID: 27526027
[TBL] [Abstract][Full Text] [Related]
12. SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth.
Lee D; Goldberg AL
J Biol Chem; 2013 Oct; 288(42):30515-30526. PubMed ID: 24003218
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol prevents TNF-α-induced muscle atrophy via regulation of Akt/mTOR/FoxO1 signaling in C2C12 myotubes.
Wang DT; Yin Y; Yang YJ; Lv PJ; Shi Y; Lu L; Wei LB
Int Immunopharmacol; 2014 Apr; 19(2):206-13. PubMed ID: 24534773
[TBL] [Abstract][Full Text] [Related]
14. [The role of Foxo1 and ubiquitin-proteasome system markers in muscle atrophy caused by chronic kidney disease].
Yin J; Huang J; Yuan W; Gu L; Wang L; Shang M
Zhonghua Nei Ke Za Zhi; 2014 Jan; 53(1):31-4. PubMed ID: 24674725
[TBL] [Abstract][Full Text] [Related]
15. Myostatin induces degradation of sarcomeric proteins through a Smad3 signaling mechanism during skeletal muscle wasting.
Lokireddy S; McFarlane C; Ge X; Zhang H; Sze SK; Sharma M; Kambadur R
Mol Endocrinol; 2011 Nov; 25(11):1936-49. PubMed ID: 21964591
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms involved in 3',5'-cyclic adenosine monophosphate-mediated inhibition of the ubiquitin-proteasome system in skeletal muscle.
Gonçalves DA; Lira EC; Baviera AM; Cao P; Zanon NM; Arany Z; Bedard N; Tanksale P; Wing SS; Lecker SH; Kettelhut IC; Navegantes LC
Endocrinology; 2009 Dec; 150(12):5395-404. PubMed ID: 19837877
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy.
Reed SA; Sandesara PB; Senf SM; Judge AR
FASEB J; 2012 Mar; 26(3):987-1000. PubMed ID: 22102632
[TBL] [Abstract][Full Text] [Related]
18. Imoxin prevents dexamethasone-induced promotion of muscle-specific E3 ubiquitin ligases and stimulates anabolic signaling in C2C12 myotubes.
Eo H; Reed CH; Valentine RJ
Biomed Pharmacother; 2020 Aug; 128():110238. PubMed ID: 32450522
[TBL] [Abstract][Full Text] [Related]
19. Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: an in vitro and in vivo study.
Yuan L; Han J; Meng Q; Xi Q; Zhuang Q; Jiang Y; Han Y; Zhang B; Fang J; Wu G
Oncol Rep; 2015 May; 33(5):2261-8. PubMed ID: 25760630
[TBL] [Abstract][Full Text] [Related]
20. Cryptotanshinone prevents muscle wasting in CT26-induced cancer cachexia through inhibiting STAT3 signaling pathway.
Chen L; Yang Q; Zhang H; Wan L; Xin B; Cao Y; Zhang J; Guo C
J Ethnopharmacol; 2020 Oct; 260():113066. PubMed ID: 32505837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
